Enoxacin for Amyotrophic Lateral Sclerosis (REALS-1 Trial)

"Affirmative. Clinicaltrials.gov data reveals that this experimental trial, launched on March 26th 2021, is actively recruiting volunteers. A total of 36 participants are needed from one designated medical facility."

"At the present moment, there is only one running clinical trial investigating Enoxacin. This phase 3 research has yet to be concluded and takes place mainly in Montreal, Quebec with a single additional location."

"Apotex Inc. initiated the research into Enoxacin in 2021, which saw a trial of 36 participants. This led to Phase 1 and 2 drug approval stages being passed successfully. There is currently one active study sponsored by Apotex Inc.."

"This medical experiment requires patients to be between 18 and 85 years old. Separately, there are 44 trials for minors and 395 studies targeting older adults."

"This trial is recruiting 36 patients with amyotrophic lateral sclerosis, aged 18 to 85. To be eligible they must have a familial or sporadic ALS diagnosis, FVC of at least 50 percent predicted, not currently breastfeeding/pregnant (if female), been on riluzole for 30 days, completed one cycle of edaravone if applicable, not taking theophylline-containing meds or clozapine and duloxetine in the past month, no active infections recently and abstained from fluoroquinolones for 30 days prior to randomisation."

"As recorded on clinicaltrials.gov, this medical research is currently enrolling participants. It was initially announced on March 26th 2021 and has been up to date as recently as August 10th 2022."